Trial achieved biological proof-of-concept, dose discovery and biomarker improvement San Diego, California, November 4, 2025 – Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) (“Thiogenesis” or the “Company”) a clinical-stage biotechnology company developing sulfur-based therapeutics for pediatric diseases, predominantly those involving mitochondrial dysfunction, today announced interim results from its Phase 2 clinical trial of TTI-0102 for Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes or MELAS, which is being conducted at Radboud University in the Netherlands and ...
[ more ]
